| Identification | Back Directory | [Name]
(S)-CFT7455 | [CAS]
2504235-67-8 | [Synonyms]
CFT7455
(S)-CFT7455
(S)-3-(6-(4-(morpholinomethyl)benzyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione | [Molecular Formula]
C28H27N3O4 | [MOL File]
2504235-67-8.mol | [Molecular Weight]
469.54 |
| Chemical Properties | Back Directory | [Boiling point ]
738.0±60.0 °C(Predicted) | [density ]
1.347±0.06 g/cm3(Predicted) | [solubility ]
Acetonitrile: Sparingly Soluble: 1-10 mg/ml
DMSO: Sparingly Soluble: 1-10 mg/ml | [form ]
Solid | [pka]
10.70±0.40(Predicted) | [color ]
Light yellow to green yellow | [InChIKey]
MUKCJOOKCZSQNW-FKEMPHOKNA-N | [SMILES]
C(C1C=CC(CN2CCOCC2)=CC=1)C1=CC=C2N([C@H]3CCC(=O)NC3=O)C(=O)C3C=CC=C1C2=3 |&1:19,r| |
| Hazard Information | Back Directory | [Uses]
Cemsidomide (CFT7455) is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity[1]. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells. | [in vivo]
In mouse xenograft tumor models, Cemsidomide demonstrates dose dependent efficacy from 3 μg/kg/day to 100 μg/kg/day. In several tumor xenografts tested daily dosing of Cemsidomide at dose of 30 μg/kg/day to 100 μg/kg/day led to durable tumor regression[1].
Cemsidomide (0.1 mg/kg/day; for 21 days) promotes tumor regression in the H929 tumor xenograft model (95% tumor growth inhibition by 7 days)[2]. | [IC 50]
Cereblon: 0.9 nM (Kd) | [References]
[1] David Proia, et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1.
[2] James A. Henderson, et al. Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models. Cancer Res (2021) 81 (13_Supplement): LB007. |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|